|
Federal
Register Notices > Notices
of Application - 2001 > Cerilliant Corporation
[Federal Register: February 14, 2001 (Volume 66,
Number 31)]
[Notices]
[Page 10320-10321]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14fe01-87]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of
Application
Pursuant to section 1301.33(a) of Title 21 of the
Code of Federal Regulations (CFR), this is notice that on August 23, 2000,
and December 5, 2000, Cerilliant Corporation, 14050 Summit Drive #121,
P.O. Box 201088, Austin, Texas 78708-0189, made application by letter to
the Drug Enforcement Administration (DEA) for registration as a bulk
manufacturer of the basic classes of controlled substances listed below:
|
Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| N-Ethylamphetamine (1475) |
I |
| N,N-Dimethylamphetamine (1480) |
I |
| Aminorex (1585) |
I |
| 4-Methylaminorex (cis isomer)
(1590) |
I |
| Gamma hydroxybutyric acid (2010) |
I |
| Methaqualone (2565) |
I |
| Alpha-Ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide (7315) |
I |
| Tetrahydrocannabinols (7370) |
I |
| Mescaline (7381) |
I |
| 3,4,5-Trimethoxyamphetamine
(7390) |
I |
| 4-Bromo-2,5-dimethoxyamphetaime
(7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine
(7392) |
I |
| 4-Methyl-2,5-dimethoxyamphetamine
(7395) |
I |
| 2,5-Dimethoxyamphetamine (7396) |
I |
| 2,5-Dimethoxy-4-ethylamphetamine
(7399) |
I |
| 3,4-Methylenedioxyamphetamine
(7400) |
I |
| 5-Methoxy-3,4-methylenedioxyamphetamine
(7401) |
I |
| N-Hydroxy-3,4-methylenedioxyamphetamine
(7402) |
I |
| 3,4-Methylenedioxy-N-ethylamphetamine
(7404) |
I |
| 3,4-Methylenedioxymethamphetamine
(7405) |
I |
| 4-Methoxyamphetamine (7411) |
I |
| Bufotenine (7433) |
I |
| Diethyltryptamine (7434) |
I |
| Dimethyltryptamine (7435) |
I |
| Psilocybin (7437) |
I |
| Psilocyn (7438) |
I |
| Acetyldihydrocodeine (9051) |
I |
| Benzylmorphine (9052) |
I |
| Codeine-N-oxide (9053) |
I |
| Dihydromorphine (9145) |
I |
| Heroin (9200) |
I |
| Morphine-N-oxide (9307) |
I |
| Normorphine (9313) |
I |
| Pholcodine (9314) |
I |
| Acetylmethadol (9601) |
I |
| Allyprodine (9602) |
I |
| Alphacetylmethadol except
Levo-Alphacetylmethadol (9603) |
I |
| Alphameprodine (9604) |
I |
| Alphamethadol (9605) |
I |
| Betacetylmethadol (9607) |
I |
| Betameprodine (9608) |
I |
| Betamethadol (9609) |
I |
| Betaprodine (9611) |
I |
| Hydromorphinol (9627) |
I |
| Noracymethadol (9633) |
I |
| Norlevorphanol (9634) |
I |
| Normethadone (9635) |
I |
| Trimeperidine (9646) |
I |
| Para-Fluorofentanyl (9812) |
I |
| 3-Methylfentanyl (9813) |
I |
| Alpha-methylfentanyl (9814) |
I |
| Acetyl-alpha-methylfentanyl
(9815) |
I |
| Beta-hydroxyfentanyl (9830) |
I |
| Beta-hydroxy-3-methylfentanyl
(9831) |
I |
[[Page 10321]]
|
Drug |
Schedule |
| Alpha-Methylthiofentanyl (9832) |
I |
| 3-Methylthiofentanyl (9833) |
I |
| Thiofentanyl (9835) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Phenmetrazine (1631) |
II |
| Methylphenidate (1724) |
II |
| Amobarbital (2125) |
II |
| Pentobarbital (2270) |
II |
| Secobarbital (2315) |
II |
| Glutethimide (2550) |
II |
| Nabilone (7379) |
II |
| 1-Phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
II |
| 1-Piperidinocyclohexanecarbonitrile
(8603) |
II |
| Alphaprodine (9010) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Dihydrocodeine (9120) |
II |
| Oxycodone (9143) |
II |
| Hydromorphone (9150) |
II |
| Diphenoxylate (9170) |
II |
| Benzoylecgonine (9180) |
II |
| Ethylmorphine (9190) |
II |
| Hydrocodone (9193) |
II |
| Levomethorphan (9210) |
II |
| Levorphanol (9220) |
II |
| Isomethadone (9226) |
II |
| Meperidine (9230) |
II |
| Methadone (9250) |
II |
| Methadone-intermediate (9254) |
II |
| Morphine (9300) |
II |
| Thebaine (9333) |
II |
| Levo-alphacetylmethadol (9648) |
II |
| Oxymorphone (9652) |
II |
| Noroxymorphone (9668) |
II |
| Alfentanil (9737) |
II |
| Sufentanil (9740) |
II |
| Fentanyl (9801) |
II |
The firm plans to manufacture small quantities of
the listed controlled substances to make deuterated and non-deuterated
drug reference standards which will be distributed to analytical and
forensic laboratories for drug testing programs.
Any other such applicant and any person who is
presently registered with DEA to manufacture such substances may file
comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed, in
quintuplicate, to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, United States Department of
Justice, Washington, DC 20537, Attention: DEA Federal Register
Representative (CCR), and must be filed no later than April 16, 2001.
Dated: January 25, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 01-3752 Filed 2-13-01; 8:45 am]
BILLING CODE 4410-09-M
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
Registration
Support
Toll Free Number: 1-800-882-9539
ARCOS
| Career Opportunities | Chemical Program |
Controlled
Substance Schedules | Drugs and
Chemicals of Concern
Electronic Commerce Initiatives | | Federal Register
Notices | Import Export | Links
| Meetings
and Events | NFLIS
Offices &
Directories | On-Line Forms & Applications |
Program
Description | Publications
|
Questions & Answers | Quotas
Reports Required by 21 CFR | Title 21 Regulations & Codified
CSA
Contact Us | Home
| Hot
Items | Site Map | Search | What's New
|
